Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

por Uhara, H., Kiyohara, Y., Tsuda, A., Takata, M., Yamazaki, N.
Publicado 2017

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level

por Sakaizawa, K, Goto, Y, Kiniwa, Y, Uchiyama, A, Harada, K, Shimada, S, Saida, T, Ferrone, S, Takata, M, Uhara, H, Okuyama, R
Publicado 2012

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma

por Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., Tokudome, T.
Publicado 2015

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

por Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Publicado 2015